Welcome To Jupiter Biomedical Research

Jupiter Biomedical Research, Inc. was created to commercialize two promising development candidates, JBR-102, targeting specific cancer indications, and JBR-201 as an antiviral therapeutic.

Cancer Treatment

The Company has discovered and advanced a new chemical entity (internally referenced as JBR-102), through preclinical, IND-enabling studies for treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer. Initially formulated as an intravenous drug for the treatment of late stage glioblastoma multiforme in near-terminal patients, JBR-102 is being redesigned as an oral formulation for the management of both early and late stage GBM along with a host of other solid tumor and hematologic cancer target indications including prostate cancer, lung cancer, colon cancer, melanoma, and one hematologic malignant (blood cancer) cell line.

Early preclinical investigations demonstrated the in vitro potency of JBR-102 against active cell cultures of both brain and lung cancer cell lines. Notably, JBR-102's anti-cancer potential was effective regardless of the cellular status of the cancer cell, i.e., the drug's potency remained whether cells were actively growing or in one of the preparatory phases of biosynthesis leading to cell division.

Antiviral Treatment

The Company's antiviral drug candidate (JBR-201) has been successfully evaluated for activity against various measles and herpes virus strains and in several preclinical investigations including genotoxicity, safety pharmacology and animal tolerability studies. Although much of the Company's testing thus far has been focused on a connection between the Measles Virus as a putative contributing factor to Multiple Sclerosis, the Company believes that JBR-201 may also be effective against a broad spectrum of other viruses. Therefore, testing for antiviral activity against Epstein Barr, HIV and HPV (Human Papillomavirus) and a broad respiratory virus panel consisting of influenza, respiratory syncytial virus (RSV), adenovirus, parainfluenza virus, adenovirus, coronavirus (not the SARS-CoV2 type), rhinovirus, enterovirus, and human metapneumovirus is planned.